Factors Affecting the Price of Krazati

Krazati (adagrasib), a KRAS G12C inhibitor for advanced cancers, has a price shaped by key factors. 

Factors Affecting the Price of Krazati

High R&D costs, from developing this targeted therapy to extensive clinical trials for KRAS-mutated tumors like non-small cell lung cancer, drive pricing. Mirati Therapeutics’ patent exclusivity allows premium rates without generic competition. Production complexities, including specialized biologic manufacturing and strict quality control, add to expenses. Market demand for therapies addressing previously undruggable KRAS mutations and regional healthcare policies (e.g., insurance coverage) further influence patient costs.